Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

著者: Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk - The Lancet 2017 被引用: 679